KANSAS CITY, Kansas, July 25. 12, 2022 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company using its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to develop and advance a pipeline of products Next-Generation Pharmaceuticals, today announced that Chief Financial Officer (CFO), Lou Van Horn, has been named the 2022 Chief Financial Officer of the Year by the Kansas City Business Journal. This milestone marks the second time Lou has received this honor.
Lou was one of 16 CFOs representing the very best in financial management and proved invaluable to their businesses and organizations. A panel of independent judges selected this year’s winners who were celebrated at a special ceremony on July 22 at the Loews Kansas City Hotel.
“Lou’s character, expertise and principled leadership make him one of the best CFOs in our industry,” said Shane J. Schaffer, president and CEO of Cingulate. “His dedication, loyalty and values make me proud to call him a good friend.”
Lou, who helped take Cingulate public in 2021 on the Nasdaq, expressed his gratitude to the Kansas City Business Journaladding that he and the Cingulate team are excited about the region’s economic future.
“I am deeply touched by this great honor,” commented Lou. “Kansas City is such a special place to live and work, and while the past two years have presented unique challenges and difficult economic circumstances for businesses and CFOs across the country, Cingulate couldn’t be more excited about the future. or prouder to call Kansas City home.This community remains one of the best places in the entire Midwest to do business.
About Louis G. Van Horn
Lou is a strategic finance leader with over 35 years of experience in leadership roles in various industries, including pharmaceutical companies as well as global accounting firms.
Prior to joining Cingulate, Lou was Executive Vice President and Chief Financial Officer at Store Financial Services, LLC. During his tenure, he led the finance organization, while also serving, at times, as Chief Operating Officer and a member of the Board of Directors. Previously, Lou served as vice president and controller of Kansas City Southern, an NYSE company, for 16 years. Earlier in his career, he held positions in finance and accounting at Shell Oil Company, Yellow Freight Systems and PricewaterhouseCoopers. Lou has extensive experience on corporate and not-for-profit boards and has also been recognized by the Kansas City Business Journal as CFO of the Year in 2012.
Cingulate Inc. (NASDAQ: CING), is a clinical-stage biopharmaceutical company that uses its proprietary PTR™ drug delivery platform technology to create and advance a portfolio of next-generation pharmaceutical products designed to improve the lives of patients with commonly diagnosed diseases. characterized by heavy daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of ADHD, Cingulate is identifying and evaluating additional therapeutic areas where PTR™ technology could be used to develop future product candidates, including to treat anxiety disorders.
Cingulate is headquartered in Kansas City.
For more information, visit Cingulate.com
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include all statements, other than statements of historical facts, regarding our current opinions and assumptions regarding future events affecting our business, including statements regarding our plans, assumptions, expectations, beliefs and goals with respect to product development , clinical studies, clinical and regulatory timelines, market opportunities, competitive position, business strategies, potential growth opportunities and other statements of a predictive nature.
These statements are generally identified by the use of words such as “may”, “could”, “should”, “will”, “believe”, “anticipate”, “plan”, “estimate”, “expect”. “, “to the intention of”. ”, “plan”, “continue”, “outlook”, “will”, “potential” and similar statements of a future or forward-looking nature. Readers are cautioned that any forward-looking information provided by us or on our behalf is not a guarantee of future performance. Actual results may differ materially from those contained in these forward-looking statements due to various factors disclosed in our filings with the Securities and Exchange Commission (SEC), including the “Risk Factors” section of our Annual Report on Form 10. -K. filed with the SEC on March 28, 2022. All forward-looking statements speak only as of the date they are made, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.